OncologyPipeline provides a web‑based analytics platform that aggregates oncology trial results, publications, press releases, and regulatory milestones into a searchable database. Users can filter by tumor type, therapy line, mechanism of action, and sponsor to compare efficacy metrics and model launch timelines for US and EU markets, with visualizations and exportable graphics for strategic decision‑making.
Funding
Funding not disclosed
Founders
Product
Problem
Pharmaceutical and biotech companies, as well as analysts, struggle to keep up with the rapidly expanding volume of oncology trial results, news releases, and regulatory approvals across multiple tumor types, treatment lines, and geographic markets.
Solution
OncologyPipeline offers a web‑based analytics platform that aggregates oncology clinical trial data, abstracts, publications, press releases, and regulatory milestones into a searchable database. Users can filter information by tumor, line of therapy, mechanism of action, and company, then compare topline efficacy metrics (ORR, PFS/DFS, OS) and hazard ratios across studies. The platform generates estimated launch timelines for each project using standardized filing and approval assumptions for the US and Europe, and visualizes these timelines in exportable graphics. It also calculates success‑rate statistics per tumor and per sponsor, highlights “best‑of” trials based on efficacy and regulatory designations, and provides a high‑level pipeline and landscape view to identify emerging market leaders.
Target Audience
Primary users are pharmaceutical and biotech R&D teams, market‑access analysts, and investment professionals who need timely, data‑driven insights into oncology development pipelines and competitive positioning.
Features
- Comprehensive aggregation of trial results, abstracts, publications, and press releases with advanced text‑search and multi‑dimensional filters (tumor, line, immuno‑oncology, mechanism of action, sponsor)
- Comparative therapeutic‑benefit analysis displaying ORR, PFS/DFS, OS and associated hazard ratios across selected studies
- Automated approval‑timeline modeling using industry‑standard filing and regulatory lag assumptions for US and EU markets
- Success‑rate calculations with options to include only Phase III results or to count overdue trials as negative
- “Best‑of” spotlight highlighting trials with low hazard ratios, breakthrough designations, or high‑impact journal publications
- Interactive pipeline and landscape visualizations showing total patient enrollment, sponsor activity, and projected dominance in disease areas
- Exportable charts and graphics for internal presentations, with source attribution embedded